Skip to Main Content

INFORMATION FOR

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Deputy Director, Yale Cancer Center; Co-Principal Investigator and Community Outreach Co-Leader, Cancer Disparities Firewall Project

Research Summary

Dr. Herbst is committed to maintaining Yale’s status as one of the world's top centers for cancer research and patient care, through innovative programs at the cutting edge of science and clinical practice. For example, we have a facility to investigate a patient's cancer at the molecular level giving us key molecular data that our oncologists use to pursue the most promising treatments for our patients as early as possible in the course of their disease.

His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program. and is principal investigator (PI) of the Lung Master Protocol (Lung-MAP). These trials use molecular analysis of fresh tissue biopsies to help match patients to the best novel treatment in real time, and these results provide laboratory scientists the ability to explore and uncover potential resistance mechanisms in the clinic.

Over several decades, biomarkers have been identified that help clinicians target treatment and immunotherapies for patients with corresponding genetic mutations. Dr. Herbst has led teams that brought about the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have revolutionized the field and greatly enhanced patient survival. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. His leadership in targeted therapeutics resulted in a 2020 ASCO plenary talk and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the New England Journal of Medicine.

Specialized Terms: Early phase clinical trials; Biomarker studies; Personalized medicine for cancer treatment. Immunotherapy for the treatment of cancer.

Coauthors

Research Interests

Lung Neoplasms; Medical Oncology; Thoracic Neoplasms; Clinical Trials, Phase I as Topic; Biomarkers, Pharmacological; Precision Medicine

Public Health Interests

Cancer

Selected Publications

  • 29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)Gandara D, Hua X, Tolba K, Fabrizio D, Albacker L, Brennick R, Montesion M, Oxnard G, Adam S, Hirsch F, Kelly K, Herbst R, LeBlanc M, Redman M, Wu M, Kozono D. 29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC) 2022, a31-a31. DOI: 10.1136/jitc-2022-sitc2022.0029.
  • 584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumabTolba K, Gandara D, Montesion M, Nabet B, Srivastava M, Albacker L, Redman M, Kozono D, Cummings C, Herbst R, Shames D, Fabrizio D. 584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab 2022, a610-a610. DOI: 10.1136/jitc-2022-sitc2022.0584.
  • 635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancerHerbst R, Lam W, Hellmann M, Gubens M, Aggarwal C, Weng Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Finocchiaro G, Ahn M, Luft A, Landers G, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Gutierrez M. 635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer 2022, a665-a665. DOI: 10.1136/jitc-2022-sitc2022.0635.
  • LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURAJohn T, Grohe C, Goldman J, De Marinis F, Kato T, Wang Q, Choi J, Melotti B, Fidler M, Sainsbury L, Stachowiak M, Taggart S, Wu Y, Tsuboi M, Herbst R, Tarruella M. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA Annals Of Oncology 2022, 33: s1548. DOI: 10.1016/j.annonc.2022.10.323.
  • 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURAWu Y, Tsuboi M, Grohe C, John T, Tarruella M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Herbst R. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA Annals Of Oncology 2022, 33: s1548-s1549. DOI: 10.1016/j.annonc.2022.10.324.
  • Cancer of the LungMorgensztern D, Morgensztern D, Boffa D, Chen A, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Devarakonda S, Ko J, Ko J, Soto L, Soto L, Waqar S, Waqar S, Wistuba I, Wistuba I, Herbst R. Cancer of the Lung 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.
  • P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized TrialDercle L, Gomez D, Zhao B, Kelly K, Herbst R, Redman M, Gandara D, Schwartz L. P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial Journal Of Thoracic Oncology 2022, 17: s152. DOI: 10.1016/j.jtho.2022.07.251.
  • EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLCPaz-Ares L, Reck M, Peters S, Borghaei H, Herbst R, Siddiqui M, Cuchelkar V, Bhatt K, Chakrabarti D, Wang L, Morris S, Liu S. EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC Journal Of Thoracic Oncology 2022, 17: s532-s533. DOI: 10.1016/j.jtho.2022.07.951.
  • 1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICIReckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Baghdadi T, Hines S, Minichiello K, Gandara D, Kelly K, Herbst R. 1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI Annals Of Oncology 2022, 33: s1033. DOI: 10.1016/j.annonc.2022.07.1173.
  • LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURATsuboi M, Wu Y, Grohe C, John T, Tarruella M, Wang J, Kato T, Goldman J, Kim S, Yu C, Vu H, Mukhametshina G, Akewanlop C, de Marinis F, Shepherd F, Urban D, Stachowiak M, Bolanos A, Huang X, Herbst R. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA Annals Of Oncology 2022, 33: s1413-s1414. DOI: 10.1016/j.annonc.2022.08.047.
  • SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progressHerbst R. SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress Annals Of Oncology 2022, 33: s424. DOI: 10.1016/j.annonc.2022.05.428.
  • Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)Gregorio M, Nagineni V, Ravi A, Datar I, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm D, Herbst R, Madabhushi A, Riess J, Velcheti V, Hellmann M, Gainor J, Schalper K. Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC) Cancer Research 2022, 82: 1722-1722. DOI: 10.1158/1538-7445.am2022-1722.
  • Abstract 1974: Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trialDuose D, Zhang J, Redman M, Zhang B, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Moravec R, Luthra R, Al-Atrash G, Kelly K, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C. Abstract 1974: Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial Cancer Research 2022, 82: 1974-1974. DOI: 10.1158/1538-7445.am2022-1974.
  • Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancerGonzalez-Kozlova E, Huang H, Redman M, Herbst R, Gettinger S, Bazhenova L, Xie H, Patel M, Nie K, Harris J, Argueta K, Kelly K, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Moravec R, Valle D, Kim-schulze S, Gnjatic S. Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer Cancer Research 2022, 82: 5026-5026. DOI: 10.1158/1538-7445.am2022-5026.
  • A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
  • Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, Neal J, Leal T, Patel J, Dragnev K, Waqar S, Edelman M, Sigal E, Adam S, Malik S, Blanke C, LeBlanc M, Kelly K, Redman M. Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP). Journal Of Clinical Oncology 2022, 40: 6543-6543. DOI: 10.1200/jco.2022.40.16_suppl.6543.
  • Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Kelly K, Herbst R. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Journal Of Clinical Oncology 2022, 40: 9004-9004. DOI: 10.1200/jco.2022.40.16_suppl.9004.
  • First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC.Aggarwal C, Haas A, Gordon S, Mehra R, Lee P, Bestvina C, Maldonado F, Velcheti V, Herbst R, Bell S, Gillmor R, Manzanera A, Matheny C, Aguilar-Cordova E, Aguilar L, Barone F, Tak P, Sterman D. First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC. Journal Of Clinical Oncology 2022, 40: 9037-9037. DOI: 10.1200/jco.2022.40.16_suppl.9037.
  • Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.Gonzalez-Kozlova E, Huang H, Redman M, Herbst R, Gettinger S, Bazhenova L, Xie H, Patel M, Nie K, Harris J, Argueta K, Cerami E, Hong J, Biswas R, Van Nostrand S, Kelly K, Moravec R, Del Valle D, Kim-Schulze S, Gnjatic S. Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab. Journal Of Clinical Oncology 2022, 40: 9044-9044. DOI: 10.1200/jco.2022.40.16_suppl.9044.
  • Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.Parra E, Duose D, Zhang J, Redman M, Lazcano Segura R, Marques-Piubelli M, Laberiano Fernandez C, Zhang B, Lindsay J, Moravec R, Kannan K, Luthra R, Alatrash G, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C. Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial. Journal Of Clinical Oncology 2022, 40: 9046-9046. DOI: 10.1200/jco.2022.40.16_suppl.9046.
  • A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).Skoulidis F, Redman M, Suga J, Al Baghdadi T, Villano J, Goldberg S, Villaruz L, Minichiello K, Gandara D, Herbst R, Kelly K. A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507). Journal Of Clinical Oncology 2022, 40: 9060-9060. DOI: 10.1200/jco.2022.40.16_suppl.9060.
  • 61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLCPatel S, Reuss J, Scilla K, Giaccone G, Spigel D, Ngiam C, Zhu Q, Bara I, Ding B, Herbst R. 61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLC Annals Of Oncology 2021, 32: s1398-s1399. DOI: 10.1016/j.annonc.2021.10.079.
  • 364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking statusGarassino M, Rodriguez-Abreu D, Gadgeel S, Kowalski D, Kasahara K, Felip E, Wu Y, de Castro G, Cho B, Turna H, Horinouchi H, Reck M, Hui R, Garon E, Boyer M, Mok T, Lopes G, Kobie J, Li Y, Ayers M, Cristescu R, Zhao B, Pietanza M, Herbst R. 364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status Journal For ImmunoTherapy Of Cancer 2021, 9: a391-a391. DOI: 10.1136/jitc-2021-sitc2021.364.
  • 457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Finocchiaro G, Ahn M, Luft A, Landers G, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst R. 457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) Journal For ImmunoTherapy Of Cancer 2021, 9: a485-a485. DOI: 10.1136/jitc-2021-sitc2021.457.
  • LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLCMartinez-Marti A, Majem M, Barlesi F, Costa E, Chu Q, Monnet I, Sanchez A, Dahkil S, Camidge D, He P, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Herbst R. LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC Annals Of Oncology 2021, 32: s1320. DOI: 10.1016/j.annonc.2021.08.2121.
  • Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistanceArniella M, Ravi A, Gainor J, Stewart C, Freeman S, Awad M, Forde P, Anagnostou V, Henick B, Riess J, Gibbons D, Pennell N, Velcheti V, Leshchiner I, Kim J, Digumarthy S, Mino-Kenudson M, Heymach J, Hacohen N, Rizvi N, Herbst R, Velculescu V, Brahmer J, Schalper K, Jänne P, Wolchok J, Shaw A, Getz G, Hellman M. Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance Cancer Research 2021, 81: lb197-lb197. DOI: 10.1158/1538-7445.am2021-lb197.
  • A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).Riess J, Redman M, Wheatley-Price P, Faller B, Villaruz L, Corum L, Gowda A, Srkalovic G, Osarogiagbon R, Baumgart M, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). Journal Of Clinical Oncology 2021, 39: 9024-9024. DOI: 10.1200/jco.2021.39.15_suppl.9024.
  • Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Herbst R, Kelly K. Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A). Journal Of Clinical Oncology 2021, 39: 9075-9075. DOI: 10.1200/jco.2021.39.15_suppl.9075.
  • Postoperativer Chemotherapie-Einsatz und Ergebnisse der ADAURA-Studie: Osimertinib als adjuvante Therapie beim resezierten EGFR-mutierten NSCLCGrohé C, Wu Y, John T, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M, Engel-Riedel W. Postoperativer Chemotherapie-Einsatz und Ergebnisse der ADAURA-Studie: Osimertinib als adjuvante Therapie beim resezierten EGFR-mutierten NSCLC Pneumologie 2021, 75: s18-s19. DOI: 10.1055/s-0041-1723297.
  • Patientenberichte aus ADAURA: HRQol Daten zu Osimertinib als adjuvante Therapie bei Patienten mit reseziertem EGFR-mutiertem (EGFRm) NSCLCEngel-Riedel W, Majem M, Goldman J, Grohé C, John T, Laktionov K, Kim S, Kato T, Vu H, Lu S, Lee K, Akewanlop C, Yu C, de Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst R, Wu Y, Wohlleber M. Patientenberichte aus ADAURA: HRQol Daten zu Osimertinib als adjuvante Therapie bei Patienten mit reseziertem EGFR-mutiertem (EGFRm) NSCLC Pneumologie 2021, 75: s21-s21. DOI: 10.1055/s-0041-1723302.
  • P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung CancerWalia G, Lu M, Bourla A, Santos E, Schulze K, Cabili M, Williams E, Mirkovic N, Dicecca R, Lee S, Fang B, Schwartzberg L, Herbst R, Chiang A. P09.55 A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer Journal Of Thoracic Oncology 2021, 16: s316-s317. DOI: 10.1016/j.jtho.2021.01.483.
  • Abstract PO-074: The impact of phenotypic bias in the generalizability of deep learning models in non-small cell lung cancerGilson A, Du J, Janda G, Umrao S, Joel M, Choi R, Herbst R, Krumholz H, Aneja S. Abstract PO-074: The impact of phenotypic bias in the generalizability of deep learning models in non-small cell lung cancer Clinical Cancer Research 2021, 27: po-074-po-074. DOI: 10.1158/1557-3265.adi21-po-074.
  • Abstract PO-078: Exploring adversarial image attacks on deep learning models in oncologyJoel M, Umrao S, Chang E, Choi R, Yang D, Gilson A, Herbst R, Krumholz H, Aneja S. Abstract PO-078: Exploring adversarial image attacks on deep learning models in oncology Clinical Cancer Research 2021, 27: po-078-po-078. DOI: 10.1158/1557-3265.adi21-po-078.
  • OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLCWu Y, John T, Grohe C, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC Journal Of Thoracic Oncology 2021, 16: s113-s114. DOI: 10.1016/j.jtho.2021.01.292.
  • P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI EraRemon J, Lacas B, Herbst R, Reck M, Garon E, Scagliotti G, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen H, Heymach J, Mandrekar S, Okamoto I, Neal J, Heist R, Pignon J, Besse B. P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era Journal Of Thoracic Oncology 2021, 16: s244-s245. DOI: 10.1016/j.jtho.2021.01.345.
  • FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLCHerbst R, Garon E, Kim D, Cho B, Gervais R, Perez-Gracia J, Han J, Majem M, Forster M, Monnet I, Novello S, Gubens M, Boyer M, Su W, Samkari A, Jensen E, Piperdi B, Baas P. FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC Journal Of Thoracic Oncology 2021, 16: s223-s224. DOI: 10.1016/j.jtho.2021.01.140.
  • OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400AHirsch F, Hua X, Wu M, Neal J, Cheng H, Gettinger S, Bazhenova L, Papadimitrakopoulou V, Borghaei H, Mack P, Kelly K, Herbst R, Gandara D, Redman M, Kozono D. OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A Journal Of Thoracic Oncology 2021, 16: s102. DOI: 10.1016/j.jtho.2021.01.273.
  • MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular AnalysisMack P, Minichielle K, Redman M, Tolba K, Kozono D, Waqar S, Chowdhury A, Dowlati A, Neal J, Dragnev K, Aggarwal C, Hirsch F, Kelly K, Gandara D, Herbst R. MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis Journal Of Thoracic Oncology 2021, 16: s163-s164. DOI: 10.1016/j.jtho.2021.01.196.
  • MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch F, Mack P, Kelly K, Herbst R, Gandara D, Redman M. MA11.10 Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400) Journal Of Thoracic Oncology 2021, 16: s176-s177. DOI: 10.1016/j.jtho.2021.01.254.
  • OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLCMajem M, Goldman J, John T, Grohe C, Laktionov K, Kim S, Kato T, Vu H, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst R, Wu Y. OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC Journal Of Thoracic Oncology 2021, 16: s112-s113. DOI: 10.1016/j.jtho.2021.01.291.
  • FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLCHerbst R, De Marinis F, Giaccone G, Vergnenegre A, Barrios C, Morise M, Felip E, Oprean C, Kim Y, Andric Z, Mocci S, Enquist I, Komatsubara K, Mccleland M, Deng Y, Kuriki H, Villalobos M, Phan S, Spigel D, Jassem J. FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC Journal Of Thoracic Oncology 2021, 16: s224-s225. DOI: 10.1016/j.jtho.2021.01.142.
  • 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrenceTsuboi M, Wu Y, He J, John T, Grohe C, Majem M, Goldman J, Laktionov K, Kim S, Kato T, Vu H, Akewanlop C, Yu C, de Marinis F, Domine M, Shepherd F, Yan C, Atasoy A, Herbst R. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence Annals Of Oncology 2020, 31: s1378. DOI: 10.1016/j.annonc.2020.10.349.
  • Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrenceTsuboi M, Wu Y, He J, John T, Grohe C, Majem M, Goldman J, Laktionov K, Kim S, Kato T, Vu H, Akewanlop C, Yu C, de Marinis F, Domine M, Shepherd F, Yan C, Atasoy A, Herbst R. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence Annals Of Oncology 2020, 31: s1177. DOI: 10.1016/j.annonc.2020.08.2279.
  • Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLCNishio M, Peled N, Zer A, Houghton B, Bar J, Drew D, Herbst R, Rodriguez-Abreu D, Talpur R, Golden L, Yin L, Dang T, Hui R. Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC Annals Of Oncology 2020, 31: s848-s849. DOI: 10.1016/j.annonc.2020.08.1627.
  • Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLCLiu Y, Zugazagoitia J, Schalper K, Herbst R, Rimm D. Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC Cancer Research 2020, 80: 2002-2002. DOI: 10.1158/1538-7445.am2020-2002.
  • Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancerDing A, Villarroel-Espindola F, Ducler A, Henick B, Desai S, Gianino N, Zugazagoitia J, Rimm D, Robert A, Cruzalegui F, Ferré P, Herbst R, Sanmamed M, Chen L, Schalper K. Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer Cancer Research 2020, 80: 5525-5525. DOI: 10.1158/1538-7445.am2020-5525.
  • Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Journal Of Clinical Oncology 2020, 38: lba5-lba5. DOI: 10.1200/jco.2020.38.18_suppl.lba5.
  • Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.Mack P, Redman M, Moon J, Goldberg S, Herbst R, Melnick M, Walther Z, Hirsch F, Politi K, Kelly K, Gandara D. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal Of Clinical Oncology 2020, 38: 9532-9532. DOI: 10.1200/jco.2020.38.15_suppl.9532.
  • A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.
  • Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.Herbst R, Arkenau H, Calvo E, Bendell J, Penel N, Fuchs C, McNeely S, Rasmussen E, Wang H, Oliveira J, Ferry D, Chau I. Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. Journal Of Clinical Oncology 2020, 38: 3089-3089. DOI: 10.1200/jco.2020.38.15_suppl.3089.
  • Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.Killian J, Wright C, Chan L, Danziger N, Elvin J, Vergilio J, Lin D, Williams E, Ramkissoon S, Severson E, Hemmerich A, Duncan D, Edgerly C, Tse J, McGregor K, Schrock A, Alexander B, Ross J, Redman M, Herbst R. Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial. Journal Of Clinical Oncology 2020, 38: 3622-3622. DOI: 10.1200/jco.2020.38.15_suppl.3622.
  • NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.
  • Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).Redman M, Papadimitrakopoulou V, Minichiello K, Gandara D, Hirsch F, Mack P, Schwartz L, Vokes E, Ramalingam S, Leighl N, Bradley J, LeBlanc M, Malik S, Miller V, Sigal E, Adam S, Blanke C, Kelly K, Herbst R. Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). Journal Of Clinical Oncology 2020, 38: 9576-9576. DOI: 10.1200/jco.2020.38.15_suppl.9576.
  • Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.de Marinis F, Giaccone G, Herbst R, Oprean C, Szczesna A, Boukovinas I, Bonomi L, Kim Y, Summers Y, Kurata T, Komatsubara K, Chen M, Deng Y, Kuriki H, Mocci S, Phan S, Jassem J, Spigel D. Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC. Journal Of Clinical Oncology 2020, 38: 9594-9594. DOI: 10.1200/jco.2020.38.15_suppl.9594.
  • SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).Leighl N, Redman M, Rizvi N, Hirsch F, Mack P, Schwartz L, Wade J, Irvin W, Reddy S, Crawford J, Bradley J, Stinchcombe T, Ramalingam S, Miao J, Minichiello K, Gandara D, Herbst R, Papadimitrakopoulou V, Kelly K. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). Journal Of Clinical Oncology 2020, 38: 9623-9623. DOI: 10.1200/jco.2020.38.15_suppl.9623.
  • IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).Jassem J, Herbst R, de Marinis F, Cadranel J, Csőszi T, Isla D, Chen G, Syrigos K, Cortinovis D, Hida T, Mocci S, Phan S, Enquist I, Patel H, Villalobos M, Wen X, Deng Y, Kuriki H, Spigel D, Giaccone G. IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2020, 38: e21623-e21623. DOI: 10.1200/jco.2020.38.15_suppl.e21623.
  • O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLCHerbst R, De Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C, Morise M, Font E, Andric Z, Geater S, Ozguroglu M, Mocci S, McCleland M, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, Jassem J, Spigel D. O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC Journal For ImmunoTherapy Of Cancer 2020, 8: a1. DOI: 10.1136/lba2019.1.
  • Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter TumorresektionRittmeyer A, Tsuboi M, Herbst R, John T, Majem M, Goldman J, Kim S, Yu C, Miziara J, Novello S, Urban D, Akewanlop C, ?zt?rk A, Quang B, Kowalski D, Marmol D, Marotti M, Laus G, Wu Y, Engel-Riedel W. Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter Tumorresektion Pneumologie 2020, 74: 131-131. DOI: 10.1055/s-0039-3403361.
  • LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 studyHerbst R, de Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C, Morise M, Felip E, Andric Z, Geater S, Ozguroglu M, Mocci S, McCleland M, Zou W, Enquist I, Komatsubara K, Deng Y, Kuriki H, Spigel D, Jassem J. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study Annals Of Oncology 2019, 30: xi62-xi63. DOI: 10.1093/annonc/mdz453.
  • LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042Herbst R, Lopes G, Kowalski D, Kasahara K, Wu Y, De Castro G, Cho B, Turna H, Cristescu R, Aurora-Garg D, Lunceford J, Kobie J, Ayers M, Pietanza M, Piperdi B, Mok T. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 Annals Of Oncology 2019, 30: xi63-xi64. DOI: 10.1093/annonc/mdz453.001.
  • LBA78 IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLCSpigel D, de Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios C, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Mocci S, McCleland M, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, Jassem J, Herbst R. LBA78 IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC Annals Of Oncology 2019, 30: v915. DOI: 10.1093/annonc/mdz293.
  • 1589TiP KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. 1589TiP KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) Annals Of Oncology 2019, 30: v656. DOI: 10.1093/annonc/mdz260.111.
  • 1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resectionTsuboi M, Herbst R, John T, Grohe C, Majem M, Goldman J, Kim S, Yu C, Miziara J, Novello S, Urban D, Akewanlop C, Öztürk A, Quang B, Kowalski D, Marmol D, Marotti M, Laus G, Wu Y. 1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection Annals Of Oncology 2019, 30: v589. DOI: 10.1093/annonc/mdz258.010.
  • 1482O Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042Mansfield A, Herbst R, Castro G, Hui R, Peled N, Kim D, Novello S, Satouchi M, Wu Y, Garon E, Reck M, Robinson A, Samkari A, Piperdi B, Ebiana V, Lin J, Mok T. 1482O Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 Annals Of Oncology 2019, 30: v604-v606. DOI: 10.1093/annonc/mdz260.004.
  • LBA79 Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trialsHerbst R, Lopes G, Kowalski D, Nishio M, Wu Y, de Castro G, Baas P, Kim D, Gubens M, Cristescu R, Aurora-Garg D, Albright A, Ayers M, Loboda A, Lunceford J, Kobie J, Lubiniecki G, Pietanza M, Piperdi B, Mok T. LBA79 Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials Annals Of Oncology 2019, 30: v916-v917. DOI: 10.1093/annonc/mdz394.077.
  • SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancerHerbst R. SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancer Annals Of Oncology 2019, 30: vi32. DOI: 10.1093/annonc/mdz325.
  • P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung CancerGutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Lam W, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s403. DOI: 10.1016/j.jtho.2019.08.822.
  • OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung CancerBazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s214. DOI: 10.1016/j.jtho.2019.08.423.
  • P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung CancerHerbst R, Barlesi F, Paz-Ares L, Raben D, Aggarwal C, Bothos J, Samadani R, He P, Angra N, Martinez P. P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s450-s451. DOI: 10.1016/j.jtho.2019.08.931.
  • MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung CancerReuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic A, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Zhang J, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach J, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal P, Zhang J. MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer Journal Of Thoracic Oncology 2019, 14: s293. DOI: 10.1016/j.jtho.2019.08.589.
  • MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF)Herbst R, Arkenau H, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Chao B, Ferry D, Mi G, Paz-Ares L. MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF) Journal Of Thoracic Oncology 2019, 14: s307. DOI: 10.1016/j.jtho.2019.08.615.
  • ES06.01 Recent Advances in Second Line TreatmentHerbst R. ES06.01 Recent Advances in Second Line Treatment Journal Of Thoracic Oncology 2019, 14: s27. DOI: 10.1016/j.jtho.2019.08.092.
  • MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLCSkoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings A, Elamin Y, Lam V, Zhang J, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbò F, Sacher A, Scheffler M, Ricciuti B, Venkatraman D, Rizvi H, Liu C, Johnston R, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Lacroix L, Memmott R, Madrigal J, Goldman J, Lau S, Killam J, Walther Z, Carter B, Woodcock M, Roth J, Swisher S, Leighl N, Digumarthy S, Mooradian M, Rotow J, Wolf J, Scagliotti G, Planchard D, Besse B, Bivona T, Gandara D, Garon E, Rizvi N, Camidge D, Schalper K, Herbst R, Shaw A, Neal J, Wakelee H, Brahmer J, Jänne P, Carbone D, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach J. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC Journal Of Thoracic Oncology 2019, 14: s294-s295. DOI: 10.1016/j.jtho.2019.08.591.
  • Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytesToki M, Zugazagoitia J, Altan M, Liu L, Mani N, Liu Y, Syrigos K, Chen L, Langermann S, Herbst R, Rimm D. Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes 2019, 3151-3151. DOI: 10.1158/1538-7445.sabcs18-3151.
  • Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancerGutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer 2019, ct227-ct227. DOI: 10.1158/1538-7445.sabcs18-ct227.
  • SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)Chau I, Bendell J, Soriano A, Arkenau H, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Mi G, Schelman W, Ferry D, Herbst R, Fuchs C. SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF) Annals Of Oncology 2019, 30: iv122. DOI: 10.1093/annonc/mdz157.001.
  • Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytesToki M, Zugazagoitia J, Altan M, Liu L, Mani N, Liu Y, Syrigos K, Chen L, Langermann S, Herbst R, Rimm D. Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes Cancer Research 2019, 79: 3151-3151. DOI: 10.1158/1538-7445.am2019-3151.
  • Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancerGutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer Cancer Research 2019, 79: ct227-ct227. DOI: 10.1158/1538-7445.am2019-ct227.
  • Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.Gutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study. Journal Of Clinical Oncology 2019, 37: tps9117-tps9117. DOI: 10.1200/jco.2019.37.15_suppl.tps9117.
  • Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.Hui R, Nishio M, Reck M, Rodriguez-Abreu D, Fouad T, Flaim D, Yin L, Dang T, Herbst R. Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006. Journal Of Clinical Oncology 2019, 37: tps9118-tps9118. DOI: 10.1200/jco.2019.37.15_suppl.tps9118.
  • A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).Bazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). Journal Of Clinical Oncology 2019, 37: 9014-9014. DOI: 10.1200/jco.2019.37.15_suppl.9014.
  • A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).Owonikoko T, Redman M, Byers L, Hirsch F, Mack P, Schwartz L, Bradley J, Stinchcombe T, Leighl N, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam S, Herbst R, Papadimitrakopoulou V, Gandara D. A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). Journal Of Clinical Oncology 2019, 37: 9022-9022. DOI: 10.1200/jco.2019.37.15_suppl.9022.
  • Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).Waqar S, Redman M, Arnold S, Hirsch F, Mack P, Schwartz L, Gandara D, Stinchcombe T, Leighl N, Ramalingam S, Tanna S, Raddin R, Minichiello K, Kelly K, Bradley J, Herbst R, Papadimitrakopoulou V. Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). Journal Of Clinical Oncology 2019, 37: 9075-9075. DOI: 10.1200/jco.2019.37.15_suppl.9075.
  • LBA4 Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembroHerbst R, Garon E, Kim D, Cho B, Gracia J, Han J, Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su W, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. LBA4 Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro Annals Of Oncology 2018, 29: x42-x43. DOI: 10.1093/annonc/mdy511.003.
  • Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or MelanomaCampbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
  • P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLCAltan M, Toki M, Carvajal-Hausdorf D, Gettinger S, Herbst R, Rimm D. P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC Journal Of Thoracic Oncology 2018, 13: s738. DOI: 10.1016/j.jtho.2018.08.1244.
  • LBA63 Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)Herbst R, Garon E, Kim D, Cho B, Gracia J, Han J, Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su W, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. LBA63 Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro) Annals Of Oncology 2018, 29: viii749. DOI: 10.1093/annonc/mdy424.075.
  • Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
  • Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumorsMorgado M, Datar I, Wang J, Sanmamed M, McEachern K, Jenkins D, Chen L, Carvajal-Hausdorf D, Rimm D, Herbst R, Schalper K. Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors Cancer Research 2018, 78: 1681-1681. DOI: 10.1158/1538-7445.am2018-1681.
  • Abstract 3334: CREB is required for KRAS -driven lung tumorigenesisLee J, Slack F, Nestler E, Herbst R, Koo J. Abstract 3334: CREB is required for KRAS -driven lung tumorigenesis Cancer Research 2018, 78: 3334-3334. DOI: 10.1158/1538-7445.am2018-3334.
  • Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.
  • Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
  • Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).Henick B, Datar I, Villarroel-Espindola F, Sanmamed M, Yu J, Tuktamyshov R, Li A, Toki M, Syrigos K, Rimm D, Chen L, Herbst R, Schalper K. Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). Journal Of Clinical Oncology 2018, 36: 12002-12002. DOI: 10.1200/jco.2018.36.15_suppl.12002.
  • A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.Socinski M, Von Pawel J, Kasahara K, Bondarenko I, Syrigos K, Vladimirov V, Bryl M, Zereu M, Bair A, Hilton F, Liau K, Herbst R. A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. Journal Of Clinical Oncology 2018, 36: 109-109. DOI: 10.1200/jco.2018.36.15_suppl.109.
  • Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).Datar I, Villarroel-Espindola F, Henick B, Syrigos K, Toki M, Rimm D, Ferrone S, Herbst R, Schalper K. Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 12015-12015. DOI: 10.1200/jco.2018.36.15_suppl.12015.
  • Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.Herbst R, Chau I, Petrylak D, Arkenau H, Bendell J, Santana-Davila R, Calvo E, Penel N, Martin-Liberal J, Soriano A, Cassier P, Krebs M, Isambert N, Widau R, Mi G, Jin J, Ferry D, Fuchs C, Paz-Ares L. Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. Journal Of Clinical Oncology 2018, 36: 3059-3059. DOI: 10.1200/jco.2018.36.15_suppl.3059.
  • First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.Papadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Langer C, Edelman M, Aggarwal C, Socinski M, Gettinger S, Waqar S, Griffin K, Leighl N, Owonikoko T, Bradley J, Ramalingam S, Stinchcombe T, Blanke C, Kelly K, Herbst R. First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. Journal Of Clinical Oncology 2018, 36: 9019-9019. DOI: 10.1200/jco.2018.36.15_suppl.9019.
  • Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.Owonikoko T, Redman M, Byers L, Griffin K, Hirsch F, Mack P, Gandara D, Bradley J, Stinchcombe T, Kelly K, Ramalingam S, Herbst R, Papadimitrakopoulou V. Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study. Journal Of Clinical Oncology 2018, 36: 9055-9055. DOI: 10.1200/jco.2018.36.15_suppl.9055.
  • Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).Chau I, Penel N, Arkenau H, Santana-Davila R, Calvo E, Soriano A, Mi G, Jin J, Ferry D, Herbst R, Fuchs C. Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF). Journal Of Clinical Oncology 2018, 36: 101-101. DOI: 10.1200/jco.2018.36.4_suppl.101.
  • 60 How to Promote and Organize Clinical Research in Lung CancerBarlesi F, Mazieres J, Zhou Y, Herbst R, Zalcman G. 60 How to Promote and Organize Clinical Research in Lung Cancer 2018, 628-634.e2. DOI: 10.1016/b978-0-323-52357-8.00060-3.
  • Contributors † Deceased.Adjei A, Ahn M, Amos C, Antonicelli A, Asamura H, Atwood T, Baas P, Bailey-Wilson J, Ball D, Barlesi F, Bazan J, Belderbos J, Bezjak A, Billingham L, Boffetta P, Bonifazi M, Brahmer J, Brambilla E, Brims F, Brunelli A, Bryant A, Campbell N, Carter B, Cerfolio R, Cho B, Cho W, Choy H, Chu C, Colburn G, Colt H, Costa R, Darling G, Davis M, de Groot P, de Koning H, De Leyn P, De Ruysscher D, Demiral A, Derks J, Detterbeck F, Devarakonda S, Dingemans A, Donington J, Dresler C, Dubinett S, Dy G, Erasmus J, Fairchild A, Fennell D, Fernando H, Filosso P, Flores R, Fong K, Fox J, Gandara D, Gandhi L, Gaspar L, Gasparini S, Gazdar A, Giaccone G, Girard N, Goldstraw P, Gore E, Goss G, Govindan R, Greenberg A, Grunenwald D, Guckenberger M, Gulati S, Hassan R, Hazzard C, Hegi F, Hensing T, Herbst R, Hirsch F, Horeweg N, Jablons D, Jett J, Kaufman A, Keall P, Kelly K, Kong F, Kubota K, Laird-Offringa I, Lara P, Laskin J, Le Q, Le Péchoux C, Liclican E, Lievens Y, Lin C, Loo B, Manus M, Macapinlac H, Macbeth F, Mackillop W, Maher C, Mambetsariev I, Mandrekar S, Mansfield A, Marks L, Mascaux C, Massion P, Mazieres J, McWilliams A, Mitsudomi T, Mok T, Morgensztern D, Mornex F, Mulshine J, Munden R, Nackaerts K, Nakamichi S, Noguchi M, Noonan K, Novello S, Nowak A, O’Byrne K, Ohri N, Okada M, Ostroff J, Parikh M, Park E, Park K, Pass H, Pastis N, Paz-Ares L, Pennell N, Perol M, Pillai R, Postmus P, Ramalingham S, Ramella S, Rami-Porta R, Reck M, Redman M, Reinmuth N, Ricardi U, Rice D, Ridge C, Rom W, Rosenzweig K, Ruffini E, Rusch V, Salgia R, Sanchez-Cespedes M, Saqi A, Scagliotti G, Schimmel S, Schwartz A, Senan S, Shepherd F, Siegfried J, Silvestri G, Simon G, Smit E, Solomon S, Stabile L, Steliga M, Stinchcombe T, Stollenwerk N, Sun J, Thomas A, Tsao M, Tsay J, Van Houtte P, Van Schil P, van Zandwijk N, Vansteenkiste J, Varella-Garcia M, Veronesi G, Vinod S, Vokes E, Wakelee H, Walser T, Watanabe S, Weder W, Wei B, Wistuba I, Yang J, Yankelevitz D, Yasufuku K, Yoneda K, Zalcman G, Zhou C, Zhou Y, Zips D. Contributors † Deceased. 2018, v-xi. DOI: 10.1016/b978-0-323-52357-8.01002-7.
  • Immune Checkpoint Inhibition in Lung CancerMorgensztern D, Herbst R. Immune Checkpoint Inhibition in Lung Cancer 2017, 333-344. DOI: 10.1007/978-3-319-62431-0_20.
  • 15PD In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockersDatar I, Sanmamed M, Choi J, Wang J, Henick B, Badri T, Mejias L, Lozano M, Gracia J, Velcheti V, Herbst R, Melero I, Chen L, Schalper K. 15PD In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers Annals Of Oncology 2017, 28: xi5. DOI: 10.1093/annonc/mdx710.006.
  • PS04.01 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Topic: Medical OncologyHerbst R, Wu Y, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. PS04.01 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Topic: Medical Oncology Journal Of Thoracic Oncology 2017, 12: s1576. DOI: 10.1016/j.jtho.2017.09.070.
  • MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support ToolGandara D, Herbst R, Mok T, Ramalingam S, Obholz K, Quill T, Chow H, Scagliotti G. MA 07.14 Change in Practice Patterns from an Online NSCLC Treatment Decision Support Tool Journal Of Thoracic Oncology 2017, 12: s1830-s1831. DOI: 10.1016/j.jtho.2017.09.514.
  • P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor ResectionHerbst R, Wu Y, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection Journal Of Thoracic Oncology 2017, 12: s2399-s2400. DOI: 10.1016/j.jtho.2017.11.019.
  • 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNAGoldberg S, Narayan A, Narayan A, Kole A, Kole A, Decker R, Teysir J, Teysir J, Carriero N, Lee A, Nemati R, Nemati R, Nath S, Nath S, Mane S, Deng Y, Sukumar N, Sukumar N, Zelterman D, Boffa D, Politi K, Gettinger S, Wilson L, Herbst R, Patel A. 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA Annals Of Oncology 2017, 28: v478. DOI: 10.1093/annonc/mdx380.043.
  • Co-Option of the Extracellular Matrix During Lung Cancer Metastasis and Therapeutic RepsonseStevens L, Adua S, Arnal-Estapé A, Zhao M, Barlaskar F, Herbst R, Nguyen D. Co-Option of the Extracellular Matrix During Lung Cancer Metastasis and Therapeutic Repsonse Journal Of Thoracic Oncology 2017, 12: s1543. DOI: 10.1016/j.jtho.2017.06.049.
  • Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometryVillarroel-Espindola F, Carvajal-Hausdorf D, Datar I, Esch A, Rashidi N, Nassar A, Ren S, Montgomery R, Herbst R, Rimm D, Schalper K. Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometry Cancer Research 2017, 77: 1635-1635. DOI: 10.1158/1538-7445.am2017-1635.
  • Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC)Datar I, Wang J, Mani N, Villarroel-Espindola F, Ryan P, Sanmamed M, McEachern K, Jenkins D, Rimm D, Chen L, Herbst R, Schalper K. Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC) Cancer Research 2017, 77: 5600-5600. DOI: 10.1158/1538-7445.am2017-5600.
  • Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)Villarroel-Espindola F, Datar I, Velcheti V, Rimm D, Herbst R, Schalper K. Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC) Cancer Research 2017, 77: 5657-5657. DOI: 10.1158/1538-7445.am2017-5657.
  • O-019 Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 studyArkenau H, Bendell J, Herbst R, Mi G, Jin J, Rege J, Ferry D, Chau I. O-019 Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study Annals Of Oncology 2017, 28: iii144-iii145. DOI: 10.1093/annonc/mdx262.018.
  • Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
  • Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.Datar I, Mani N, Henick B, Wurtz A, Kaftan E, Herbst R, Rimm D, Gettinger S, Politi K, Schalper K. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal Of Clinical Oncology 2017, 35: e14611-e14611. DOI: 10.1200/jco.2017.35.15_suppl.e14611.
  • Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).Henick B, Goldberg S, Narayan A, Rossi C, Rodney S, Kole A, Politi K, Gettinger S, Herbst R, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: e20652-e20652. DOI: 10.1200/jco.2017.35.15_suppl.e20652.
  • Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.Chau I, Bendell J, Calvo E, Santana-Davila R, Arkenau H, Mi G, Jin J, Rege J, Ferry D, Herbst R, Fuchs C. Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. Journal Of Clinical Oncology 2017, 35: 4046-4046. DOI: 10.1200/jco.2017.35.15_suppl.4046.
  • Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.Jalali A, Wang J, Lee W, Zhang J, Wu C, Gibbons D, Tang X, Kalhor N, Izzo J, Behrens C, Fossella F, Tsao A, Lee J, Swisher S, Heymach J, Futreal A, Wistuba I, Herbst R, Papadimitrakopoulou V, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. Journal Of Clinical Oncology 2017, 35: 8538-8538. DOI: 10.1200/jco.2017.35.15_suppl.8538.
  • A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.Wade J, Langer C, Redman M, Aggarwal C, Bradley J, Crawford J, Miao J, Griffin K, Herbst R, Kelly K, Gandara D, Papadimitrakopoulou V. A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. Journal Of Clinical Oncology 2017, 35: 9054-9054. DOI: 10.1200/jco.2017.35.15_suppl.9054.
  • Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.Aggarwal C, Redman M, Lara P, Borghaei H, Hoffman P, Bradley J, Griffin K, Miao J, Mack P, Papadimitrakopoulou V, Herbst R, Kelly K, Gandara D. Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. Journal Of Clinical Oncology 2017, 35: 9055-9055. DOI: 10.1200/jco.2017.35.15_suppl.9055.
  • A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.Edelman M, Redman M, Albain K, McGary E, Rafique N, Petro D, Waqar S, Miao J, Griffin K, Papadimitrakopoulou V, Kelly K, Gandara D, Herbst R. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. Journal Of Clinical Oncology 2017, 35: 9056-9056. DOI: 10.1200/jco.2017.35.15_suppl.9056.
  • Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Castro G, Garrido M, Ellison M, Samkari A, Lubiniecki G, Garon E. Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. Journal Of Clinical Oncology 2017, 35: 9090-9090. DOI: 10.1200/jco.2017.35.15_suppl.9090.
  • The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual MeetingKaufman H, Atkins M, Dicker A, Jim H, Garrison L, Herbst R, McGivney W, Silverstein S, Wigginton J, Yu P. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting Journal For ImmunoTherapy Of Cancer 2017, 5: 38. PMCID: PMC5394621, DOI: 10.1186/s40425-017-0241-6.
  • 143TiP IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLCJassem J, de Marinis F, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 143TiP IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC Annals Of Oncology 2017, 28: ii50. DOI: 10.1093/annonc/mdx091.063.
  • 90PD Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety dataHerbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Jin J, Mi G, Rege J, Paz-Ares L. 90PD Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data Annals Of Oncology 2017, 28: ii32-ii33. DOI: 10.1093/annonc/mdx091.010.
  • 83O A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400APapadimitrakopoulou V, Redman M, Borghaei H, Waqar S, Robert F, Kiefer G, McDonough S, Herbst R, Kelly K, Gandara D. 83O A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A Annals Of Oncology 2017, 28: ii29. DOI: 10.1093/annonc/mdx091.003.
  • Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.Hellmann M, Ma J, Garon E, Hui R, Gandhi L, Soria J, Anderson K, Lubiniecki G, Piperdi B, Herbst R. Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010. Journal Of Clinical Oncology 2017, 35: 77-77. DOI: 10.1200/jco.2017.35.7_suppl.77.
  • Cancer of the LungLu C, Morgensztern D, Chiang A, Onn A, Sepesi B, Vaporciyan A, Chang J, Komaki R, Wistuba I, Herbst R. Cancer of the Lung 2017, 1-30. DOI: 10.1002/9781119000822.hfcm085.
  • A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.Petrylak D, Arkenau H, Perez-Gracia J, Krebs M, Santana-Davila R, Yang J, Rege J, Mi G, Ferry D, Herbst R. A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. Journal Of Clinical Oncology 2017, 35: 349-349. DOI: 10.1200/jco.2017.35.6_suppl.349.
  • Lung CancerMorgensztern D, Herbst R. Lung Cancer Hematology/Oncology Clinics Of North America 2017, 31: i. DOI: 10.1016/s0889-8588(16)30151-4.
  • Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).Chau I, Bendell J, Calvo E, Santana-Davila R, Rodon Ahnert J, Penel N, Arkenau H, Yang J, Rege J, Mi G, Ferry D, Herbst R, Fuchs C. Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Journal Of Clinical Oncology 2017, 35: 102-102. DOI: 10.1200/jco.2017.35.4_suppl.102.
  • MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC) Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
  • MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung AdenocarcinomasHastings K, Hastings K, Choi J, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Oliva I, Zhao Z, Zhao Z, Gaffney S, Gaffney S, Iamarino A, Iamarino A, Zhao S, Zhao S, Bi M, Bi M, Goldberg S, Chiang A, Liu Z, Liu Z, Townsend J, Schlessinger J, Lifton R, Herbst R, Gettinger S, Politi K. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas Journal Of Thoracic Oncology 2017, 12: s435. DOI: 10.1016/j.jtho.2016.11.507.
  • P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
  • P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: ITDecker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
  • P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and BiomarkersRothberg B, Das R, Jackson L, Lazowski H, Bai Y, O'Neill D, Roberts S, Rothberg J, Herbst R, Kim A, Boffa D, Rimm D, Detterbeck F, Tanoue L. P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers Journal Of Thoracic Oncology 2017, 12: s623-s624. DOI: 10.1016/j.jtho.2016.11.801.
  • P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab Topic: BiomarkersMack P, Moon J, Herbst R, Kim E, Semrad T, Redman M, Tsai R, Solis L, Gregg J, Hatcher S, Varella-Garcia M, Hirsch F, Blanke C, Kelly K, Gandara D. P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab Topic: Biomarkers Journal Of Thoracic Oncology 2017, 12: s967-s968. DOI: 10.1016/j.jtho.2016.11.1334.
  • P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted TherapyAltan M, Pelekanou V, Schalper K, Toki M, Herbst R, Rimm D. P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy Journal Of Thoracic Oncology 2017, 12: s813-s814. DOI: 10.1016/j.jtho.2016.11.1098.
  • OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed PembrolizumabHerbst R, Garon E, Kim D, Cho B, Gadgeel S, Léna H, Gúrpide A, Han J, Arvis C, Majem M, Forster M, Monnet I, Novello S, Saka H, Szalai Z, Gubens M, Su W, Lubiniecki G, Shentu Y, Ferraro G, Baas P. OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab Journal Of Thoracic Oncology 2017, 12: s254-s255. DOI: 10.1016/j.jtho.2016.11.243.
  • P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model Topic: IT BiomarkersLee J, Zhang Y, Choi J, Sharma R, Park H, Kaftan E, Papadimitrakopoulou V, Herbst R, Koo J. P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model Topic: IT Biomarkers Journal Of Thoracic Oncology 2017, 12: s1319. DOI: 10.1016/j.jtho.2016.11.1865.
  • P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: ITDe Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giacconne G, Herbst R. P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: IT Journal Of Thoracic Oncology 2017, 12: s1299-s1300. DOI: 10.1016/j.jtho.2016.11.1837.
  • MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening UpdatesPapadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Borghaei H, Langer C, Wade J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, Mcdonough S, Sigal E, Kelly K, Herbst R. MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates Journal Of Thoracic Oncology 2017, 12: s439-s440. DOI: 10.1016/j.jtho.2016.11.513.
  • 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)De Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) Annals Of Oncology 2016, 27 DOI: 10.1093/annonc/mdw594.044.
  • 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)De Marinis F, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst R. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) Annals Of Oncology 2016, 27: ix154. DOI: 10.1016/s0923-7534(21)00638-4.
  • PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study Topic: Medical OncologyGordon M, Herbst R, Horn L, Soria J, Gandhi L, Felip E, Sequist L, Spigel D, Antonia S, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger S. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study Topic: Medical Oncology Journal Of Thoracic Oncology 2016, 11: s309-s310. DOI: 10.1016/j.jtho.2016.09.097.
  • PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: Medical OncologyHerbst R, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel D. PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients Topic: Medical Oncology Journal Of Thoracic Oncology 2016, 11: s304-s305. DOI: 10.1016/j.jtho.2016.09.091.
  • PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 AssessmentHerbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Journal Of Thoracic Oncology 2016, 11: s174-s175. DOI: 10.1016/j.jtho.2016.08.014.
  • P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Track: ImmunotherapyHerbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Track: Immunotherapy Journal Of Thoracic Oncology 2016, 11: s242-s243. DOI: 10.1016/j.jtho.2016.08.112.
  • 1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLCBarlesi F, Garon E, Kim D, Felip E, Han J, Kim J, Ahn M, Fidler M, Gubens M, Castro G, Surmont V, Li Q, Deitz A, Lubiniecki G, Herbst R. 1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC Annals Of Oncology 2016, 27: vi422. DOI: 10.1093/annonc/mdw383.19.
  • LBA38 Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Perez-Gracia J, Yang J, Rege J, Mi G, Ferry D, Paz-Ares L. LBA38 Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P) Annals Of Oncology 2016, 27: vi574. DOI: 10.1093/annonc/mdw435.34.
  • LBA48 Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, De Castro G, Garrido M, Shentu Y, Lubiniecki G, Garon E. LBA48 Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010 Annals Of Oncology 2016, 27: vi583. DOI: 10.1093/annonc/mdw435.47.
  • Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinomaChoi M, Kadara H, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee J, Lifton R, Herbst R, Wistuba I. Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma Cancer Research 2016, 76: 142-142. DOI: 10.1158/1538-7445.am2016-142.
  • Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinomaKadara H, Choi M, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee J, Lifton R, Wistuba I, Herbst R. Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma Cancer Research 2016, 76: 89-89. DOI: 10.1158/1538-7445.am2016-89.
  • Abstract 1144: Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysisShien K, Ruder D, Ileana E, Papadimitrakopoulou V, Frampton G, Behrens C, Kalhor N, Lee J, Tang X, Herbst R, Wistuba I, Izzo J. Abstract 1144: Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis Cancer Research 2016, 76: 1144-1144. DOI: 10.1158/1538-7445.am2016-1144.
  • Abstract 2334: Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancerLee J, Zhang Y, Park H, Park S, Koo J, Herbst R. Abstract 2334: Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer Cancer Research 2016, 76: 2334-2334. DOI: 10.1158/1538-7445.am2016-2334.
  • Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.
  • Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
  • HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
  • Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC).Schalper K, Mani N, Toki M, Carvajal-Hausdorf D, Herbst R, Rimm D. Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 11610-11610. DOI: 10.1200/jco.2016.34.15_suppl.11610.
  • Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.Herbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Surmont V, Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 3030-3030. DOI: 10.1200/jco.2016.34.15_suppl.3030.
  • A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.Herbst R, Bendell J, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia J, Yang J, Rege J, Ferry D, Mi G, Chau I. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal Of Clinical Oncology 2016, 34: 3056-3056. DOI: 10.1200/jco.2016.34.15_suppl.3056.
  • Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.Baas P, Garon E, Herbst R, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Barlesi F, Castro G, Garrido M, Shentu Y, Lubiniecki G, Im E, Kim D. Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC. Journal Of Clinical Oncology 2016, 34: 9015-9015. DOI: 10.1200/jco.2016.34.15_suppl.9015.
  • Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.Garon E, Herbst R, Kim D, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Gubens M, Castro G, Garrido M, Shentu Y, Im E, Lubiniecki G, Baas P. Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. Journal Of Clinical Oncology 2016, 34: 9024-9024. DOI: 10.1200/jco.2016.34.15_suppl.9024.
  • Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.Gaule P, Rehman J, Smithy J, Toki M, Han G, Neumeister V, Carvajal-Hausdorf D, Schalper K, Pelekanou V, Wasserman B, Herbst R, Rimm D. Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer. Journal Of Clinical Oncology 2016, 34: 9040-9040. DOI: 10.1200/jco.2016.34.15_suppl.9040.
  • Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).Semrad T, Redman M, Herbst R, Kim E, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Hirsch F, Kelly K, Gandara D. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 9082-9082. DOI: 10.1200/jco.2016.34.15_suppl.9082.
  • Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.Papadimitrakopoulou V, Redman M, Gandara D, Hirsch F, Mack P, Borghaei H, Langer C, Engelman J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, Malik S, Miller V, Sigal E, Kelly K, Herbst R. Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. Journal Of Clinical Oncology 2016, 34: 9088-9088. DOI: 10.1200/jco.2016.34.15_suppl.9088.
  • Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.Hirsch F, Redman M, Herbst R, Kim E, Semrad T, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Kelly K, Gandara D. Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 9090-9090. DOI: 10.1200/jco.2016.34.15_suppl.9090.
  • Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort.Presley C, Harrington E, Gippetti J, Agarwala V, Bowser B, Adelson K, Herbst R, Abernethy A, Gross C. Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort. Journal Of Clinical Oncology 2016, 34: e20621-e20621. DOI: 10.1200/jco.2016.34.15_suppl.e20621.
  • E2F8 and its target genes as novel therapeutic targets for lung cancerPark S, Lee J, Platt J, Sweasy J, Glazer P, Herbst R, Koo J. E2F8 and its target genes as novel therapeutic targets for lung cancer Journal Of Thoracic Oncology 2016, 11: s29. DOI: 10.1016/j.jtho.2015.12.048.
  • Targeting PD1 and PDL1 in lung cancer treatment: Where are we now?Herbst R. Targeting PD1 and PDL1 in lung cancer treatment: Where are we now? Journal Of Thoracic Oncology 2016, 11: s8. DOI: 10.1016/j.jtho.2015.12.012.
  • LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapyHerbst R, Kim D, Felip E, Perez-Gracia J, Garon E, Han J, Molina J, Kim J, Gervais R, Ahn M, Majem M, Fidler M, De Castro G, Garrido M, Lubiniecki G, Shentu Y, Im E, Baas P. LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy Annals Of Oncology 2015, 26: ix161. DOI: 10.1093/annonc/mdv586.03.
  • 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLCHerbst R, de Marinis F, Jassem J, Spigel D, Shankar G, Mocci S, Sandler A, Lopez-Chavez A, Li S, Giaccone G. 355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC Annals Of Oncology 2015, 26: ix103. DOI: 10.1093/annonc/mdv528.12.
  • Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancerSchalper K, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Chen L, Sanmamed M, Herbst R, Rimm D. Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer Journal For ImmunoTherapy Of Cancer 2015, 3: p415. PMCID: PMC4652522, DOI: 10.1186/2051-1426-3-s2-p415.
  • AJ-2 Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer TherapiesHerbst R. AJ-2 Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer Therapies Annals Of Oncology 2015, 26: vii5. DOI: 10.1093/annonc/mdv400.02.
  • ISY8-3 Personalized immunotherapy for advanced non-small cell lung cancerHerbst R. ISY8-3 Personalized immunotherapy for advanced non-small cell lung cancer Annals Of Oncology 2015, 26: vii16. DOI: 10.1093/annonc/mdv410.02.
  • Targeted Therapy in Solid Tumors: Lung CancerWaqar S, Morgensztern D, Herbst R. Targeted Therapy in Solid Tumors: Lung Cancer 2015, 224-230. DOI: 10.1002/9781118468678.ch23.
  • Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)McLaughlin J, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Velcheti V, Haack H, Silver M, Herbst R, LoRusso P, Rimm D. Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC) 2015, 1310-1310. DOI: 10.1158/1538-7445.am2015-1310.
  • Abstract 2094: GSK-3 is a novel target of CREB and GSK-3-CREB signaling participates in cell survival in lung cancerPark S, Lee J, Herbst R, Koo J. Abstract 2094: GSK-3 is a novel target of CREB and GSK-3-CREB signaling participates in cell survival in lung cancer 2015, 2094-2094. DOI: 10.1158/1538-7445.am2015-2094.
  • Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC)Ruder D, Papadimitrakopoulou V, Shien K, Kalhor N, Lee J, Hong W, Tang X, Girard L, Minna J, Diao L, Wang J, Hanson N, Sun J, Miller V, Frampton G, Herbst R, Wistuba I, Izzo J. Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC) 2015, 3576-3576. DOI: 10.1158/1538-7445.am2015-3576.
  • Abstract 745: Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancerShien K, Papadimitrakopoulou V, Ruder D, Hanson N, Kalhor N, Lee J, Hong W, Tang X, Herbst R, Girard L, Minna J, Kurie J, Wistuba I, Izzo J. Abstract 745: Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancer 2015, 745-745. DOI: 10.1158/1538-7445.am2015-745.
  • Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.
  • Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Syrigos K, Herbst R, Rimm D. Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. Journal Of Clinical Oncology 2015, 33: 3067-3067. DOI: 10.1200/jco.2015.33.15_suppl.3067.
  • Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.Horn L, Spigel D, Gettinger S, Antonia S, Gordon M, Herbst R, Sequist L, Chappey C, Kowanetz M, Sandler A, Soria J. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. Journal Of Clinical Oncology 2015, 33: 8029-8029. DOI: 10.1200/jco.2015.33.15_suppl.8029.
  • 48 Phase I Trials TodayMorgensztern D, LoRusso P, Boerner S, Herbst R, Eder J. 48 Phase I Trials Today 2015, 661-676.e2. DOI: 10.1016/b978-1-4557-4066-6.00048-2.
  • Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280AKowanetz M, Rabe C, Xiao Y, Wu Q, Koeppen H, Leddy C, Patel R, Powderly J, Kohrt H, Gettinger S, Soria J, Herbst R, Desai R, Denker M, Ruppel J, Boe M, Nakamura R, Fu L, Sumiyoshi T, Mokatrin A, Shen X, Fine G, Chen D, Hegde P. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A Journal For ImmunoTherapy Of Cancer 2014, 2: p136. PMCID: PMC4288453, DOI: 10.1186/2051-1426-2-s3-p136.
  • Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCCHedberg M, Goh G, Freilino M, Zeng Y, Lui V, Herbst R, Lifton R, Grandis J. Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCC 2014, 985-985. DOI: 10.1158/1538-7445.am2014-985.
  • Abstract 5049: Physician preferences in tobacco cessation support for cancer patients: A survey of physicians at National Cancer Institute Designated Cancer CentersPommerenke A, Pommerenke A, Alberg A, Alberg A, Brandon T, Brandon T, Croghan I, Croghan I, Cummings M, Cummings M, Dresler C, Dresler C, Gritz E, Gritz E, Herbst R, Leischow S, Leischow S, Marshall J, Marshall J, Toll B, Warren G, Warren G. Abstract 5049: Physician preferences in tobacco cessation support for cancer patients: A survey of physicians at National Cancer Institute Designated Cancer Centers 2014, 5049-5049. DOI: 10.1158/1538-7445.am2014-5049.
  • MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer ModelsFurutani S, Komaki R, Smith P, Jürgensmeier J, Takahashi O, Rabin T, Herbst R, O'Reilly M. MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s796. DOI: 10.1016/j.ijrobp.2014.05.2300.
  • Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma.Goldberg S, Narayan A, Narayan A, Carriero N, Nemati R, Nemati R, Bommakanti A, Bommakanti A, Wurtz A, Boffa D, Decker R, Herbst R, Juergensmeier J, Juergensmeier J, Politi K, Gettinger S, Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 8093-8093. DOI: 10.1200/jco.2014.32.15_suppl.8093.
  • BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).Papadimitrakopoulou V, Lee J, Wistuba I, Tsao A, Fossella F, Heymach J, Kalhor N, Gupta S, Gettinger S, Byers L, Izzo J, Miller V, Diao L, Wang J, Wei C, Coombes K, Mauro D, Rubin E, Hong W, Herbst R. BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8042-8042. DOI: 10.1200/jco.2014.32.15_suppl.8042.
  • A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.Arkenau H, Mateo J, Lemech C, Infante J, Burris H, Bang Y, Eder J, Herbst R, Sharma S, Chung H, Decordova S, Swales K, Garrett M, Loftiss J, Durante M, Russo M, Suttle B, Motwani M, Kumar R, De Bono J. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. Journal Of Clinical Oncology 2014, 32: 2514-2514. DOI: 10.1200/jco.2014.32.15_suppl.2514.
  • The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.Tran H, Legendre B, Kim E, Blumenschein G, Tsao A, Herbst R, Wistuba I, Lewis M, Richardson K, Hong W, Heymach J. The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. Journal Of Clinical Oncology 2014, 32: 8058-8058. DOI: 10.1200/jco.2014.32.15_suppl.8058.
  • Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).McLaughlin J, Schalper K, Carvajal-Hausdorf D, Velcheti V, Haack H, Silver M, Goldberg S, Herbst R, Rimm D. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8064-8064. DOI: 10.1200/jco.2014.32.15_suppl.8064.
  • Clinical significance of TILs subtypes in non-small cell lung cancer.Schalper K, Brown J, McLaughlin J, Herbst R, Rimm D. Clinical significance of TILs subtypes in non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: 8082-8082. DOI: 10.1200/jco.2014.32.15_suppl.8082.
  • The KRAS -variant and treatment response in BATTLE-1.Weidhaas J, Kim E, Herbst R, Yu J, Slack F, Blumenschein G, Tsao A, Wistuba I, Lee J, Papadimitrakopoulou V, Hong W, Heymach J, Tran H. The KRAS -variant and treatment response in BATTLE-1. Journal Of Clinical Oncology 2014, 32: 8135-8135. DOI: 10.1200/jco.2014.32.15_suppl.8135.
  • Addressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients.Pommerenke A, Pommerenke A, Alberg A, Alberg A, Gritz E, Gritz E, Cummings K, Cummings K, Brandon T, Brandon T, Croghan I, Croghan I, Dresler C, Dresler C, Herbst R, Leischow S, Leischow S, Marshall J, Marshall J, Toll B, Warren G, Warren G. Addressing findings from the 2014 Surgeon General’s Report: Physician preference for supporting tobacco cessation in cancer patients. Journal Of Clinical Oncology 2014, 32: e17508-e17508. DOI: 10.1200/jco.2014.32.15_suppl.e17508.
  • Standardizing measurement of tobacco use in cancer clinical trials.Land S, Land S, Toll B, Warren G, Warren G, Brandon T, Brandon T, Mitchell S, Mitchell S, Dresler C, Dresler C, Gritz E, Gritz E, Schnoll R, Schnoll R, Sarna L, Sarna L, Moinpour C, Moinpour C, Ostroff J, Ostroff J, Khuri F, Khuri F, Buckner J, Buckner J, Cummings K, Cummings K, Herbst R, Shields P, Shields P, Duffy S, Duffy S, Rigotti N, Rigotti N, Prindiville S, Prindiville S, Abrams J, Abrams J. Standardizing measurement of tobacco use in cancer clinical trials. Journal Of Clinical Oncology 2014, 32: e17658-e17658. DOI: 10.1200/jco.2014.32.15_suppl.e17658.
  • A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.Herbst R, Gurpide A, Surmont V, Kim D, Waqar S, Herder J, Lee D, Carcereny E, Reguart N, Wallmark J, Ramalingam S, Langer C, Lubiniecki G, Knowles J, Zhou H, Hanson M, Baas P. A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: tps8124-tps8124. DOI: 10.1200/jco.2014.32.15_suppl.tps8124.
  • Abstract B04: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms.Lee J, Park H, Park S, Herbst R, Koo J. Abstract B04: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms. Clinical Cancer Research 2014, 20: b04-b04. DOI: 10.1158/1078-0432.14aacriaslc-b04.
  • Abstract PR03: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms.Lee J, Park H, Park S, Herbst R, Koo J. Abstract PR03: Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms. Clinical Cancer Research 2014, 20: pr03-pr03. DOI: 10.1158/1078-0432.14aacriaslc-pr03.
  • Tyrosine-kinase inhibitors in oncologyTsao A, Papadimitrakopoulou V, Herbst R. Tyrosine-kinase inhibitors in oncology 2013, 872-883. DOI: 10.1017/cbo9781139046947.083.
  • IS7–2 Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From the Battle Trial to Master ProtocolsHerbst R. IS7–2 Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From the Battle Trial to Master Protocols Annals Of Oncology 2013, 24: ix19. DOI: 10.1093/annonc/mdt447.2.
  • BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).Papadimitrakopoulou V, Wistuba I, Lee J, Tsao A, Kalhor N, Fossella F, Heymach J, Alden C, Gettinger S, Coombes K, Saintigny P, Tang X, Duffield E, Boyer J, Davis S, Powis G, Mauro D, Rubin E, Hong W, Herbst R. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: tps8118-tps8118. DOI: 10.1200/jco.2013.31.15_suppl.tps8118.
  • Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).Velcheti V, Schalper K, Carvajal D, Chen L, Sznol M, Gettinger S, Herbst R, Rimm D. Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 11075-11075. DOI: 10.1200/jco.2013.31.15_suppl.11075.
  • Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers.Warren G, Warren G, Marshall J, Marshall J, Cummings K, Cummings K, Toll B, Gritz E, Gritz E, Hutson A, Hutson A, Dibaj S, Dibaj S, Herbst R, Mulshine J, Mulshine J, Hanna N, Hanna N, Dresler C, Dresler C. Addressing tobacco use and cessation in cancer patients: Practices, perceptions, and barriers reported by oncology providers. Journal Of Clinical Oncology 2013, 31: 1561-1561. DOI: 10.1200/jco.2013.31.15_suppl.1561.
  • A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.Herbst R, Gordon M, Fine G, Sosman J, Soria J, Hamid O, Powderly J, Burris H, Mokatrin A, Kowanetz M, Leabman M, Anderson M, Chen D, Hodi F. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal Of Clinical Oncology 2013, 31: 3000-3000. DOI: 10.1200/jco.2013.31.15_suppl.3000.
  • Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).Spigel D, Gettinger S, Horn L, Herbst R, Gandhi L, Gordon M, Cruz C, Conkling P, Cassier P, Antonia S, Burris H, Fine G, Mokatrin A, Kowanetz M, Shen X, Chen D, Soria J. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 8008-8008. DOI: 10.1200/jco.2013.31.15_suppl.8008.
  • Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.Platt A, Elvin P, Morten J, Ji Q, Donald E, Womack C, Su X, Zheng L, Gladwin A, Vasselli J, Lee J, De Boer R, Herbst R. Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. Journal Of Clinical Oncology 2013, 31: 8045-8045. DOI: 10.1200/jco.2013.31.15_suppl.8045.
  • Abstract 4382: Genome-Wide Gene Expression analysis and molecular portraits regulated by NASEp, an inhibitor of CREB and CBP interaction, in non-small cell lung cancer.Park S, Platt J, Park H, Lee J, Stern D, Herbst R, Koo J. Abstract 4382: Genome-Wide Gene Expression analysis and molecular portraits regulated by NASEp, an inhibitor of CREB and CBP interaction, in non-small cell lung cancer. Cancer Research 2013, 73: 4382-4382. DOI: 10.1158/1538-7445.am2013-4382.
  • Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model.Takahashi O, Komaki R, Jürgensmeier J, Smith P, Wistuba I, Tailor R, Jacoby J, Korshunova M, Kim Y, Erez B, Herbst R, O'Reilly M. Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model. Cancer Research 2013, 73: 1042-1042. DOI: 10.1158/1538-7445.am2013-1042.
  • Abstract 2878: Targeting the CXCL5-CXCR2-CREB signaling axis suppresses growth, survival, and invasion of lung adenocarcinoma.Park H, Lee J, Saintigny P, Kurie J, Herbst R, Koo J. Abstract 2878: Targeting the CXCL5-CXCR2-CREB signaling axis suppresses growth, survival, and invasion of lung adenocarcinoma. Cancer Research 2013, 73: 2878-2878. DOI: 10.1158/1538-7445.am2013-2878.
  • Abstract 3414: Disruption of CREB-CREBBP association by 2-Naphthol AS-E phosphate induces cell cycle arrest and apoptosis in non-small cell lung cancer cells .Lee J, Park H, Ryu S, Koch P, Boyer J, Morgensztern D, Herbst R, Koo J. Abstract 3414: Disruption of CREB-CREBBP association by 2-Naphthol AS-E phosphate induces cell cycle arrest and apoptosis in non-small cell lung cancer cells . Cancer Research 2013, 73: 3414-3414. DOI: 10.1158/1538-7445.am2013-3414.
  • Abstract 3938: Role of Chi3l1/YKL-40 in the tumor progression and metastasis in the lung.Lee C, Ma B, Koo J, Herbst R, Elias J. Abstract 3938: Role of Chi3l1/YKL-40 in the tumor progression and metastasis in the lung. Cancer Research 2013, 73: 3938-3938. DOI: 10.1158/1538-7445.am2013-3938.
  • L4.1 Evolution of Battle Trials at Md Anderson Cancer CenterHong W, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee J, Lippman S. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center Annals Of Oncology 2012, 23: v7. DOI: 10.1016/s0923-7534(20)31272-2.
  • Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.
  • Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.
  • Abstract 5605: LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancerByers L, Diao L, Wang J, Girard L, Peyton M, Gazdar A, Groth P, Paul J, Liu N, Kim E, Mauro D, Herbst R, Papadimitrakopoulou V, Coombes K, Weinstein J, Minna J, Heymach J. Abstract 5605: LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer Cancer Research 2012, 72: 5605-5605. DOI: 10.1158/1538-7445.am2012-5605.
  • Abstract 648: Tobacco assessment in actively accruing Cooperative Group clinical trialsWarren G, Warren G, Peters E, Peters E, Torres E, Torres E, Cummings K, Cummings K, Gritz E, Gritz E, Hyland A, Hyland A, Herbst R, Marshall J, Marshall J, Toll B. Abstract 648: Tobacco assessment in actively accruing Cooperative Group clinical trials Cancer Research 2012, 72: 648-648. DOI: 10.1158/1538-7445.am2012-648.
  • Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cellsErickson H, Hanson N, Tran H, Mills G, Kim E, Heymach J, Wistuba I, Galindo H, Stemke-Hale K, Giri U, McDowell C, Girard L, Lee J, Herbst R, Minna J, Bischoff F. Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cells Clinical Cancer Research 2012, 18: a12-a12. DOI: 10.1158/1078-0432.12aacriaslc-a12.
  • Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time PeriodsWei X, Allen P, O'Reilly M, Fossella F, Liao Z, Heymach J, Herbst R, Chang J, Cox J, Komaki R. Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time Periods International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s588. DOI: 10.1016/j.ijrobp.2011.06.1102.
  • Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.Soulieres D, Wolf J, Shepherd F, Cappuzzo F, Bunn P, Herbst R, Hirsch F, Kerr K, Mitsudomi T, Tsao M, Yang C, Richardson F, Klughammer B, Wacker B, Sternberg D, Davies A. Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. Journal Of Clinical Oncology 2011, 29: 7533-7533. DOI: 10.1200/jco.2011.29.15_suppl.7533.
  • Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.Tsao A, Liu S, Lee J, Alden C, Kim E, Blumenschein G, Herbst R, Lippman S, Wistuba I, Hong W. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. Journal Of Clinical Oncology 2011, 29: 7550-7550. DOI: 10.1200/jco.2011.29.15_suppl.7550.
  • Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinomaCascone T, Saigal B, Reynolds D, Erez B, Jacoby J, Nilsson M, Lin H, Herbst R, Langley R, Heymach J. Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma Cancer Research 2011, 71: 3269-3269. DOI: 10.1158/1538-7445.am2011-3269.
  • Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRASSaintigny P, Diao L, Wang J, Girard L, Lin S, Coombes K, Liu S, Lee J, Weinstein J, Xie Y, Fan Y, Tang X, Kim E, Herbst R, Tsao A, Blumenschein G, Mao L, Lippman S, Minna J, Hong W, Wistuba I, Heymach J. Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS Cancer Research 2011, 71: 4109-4109. DOI: 10.1158/1538-7445.am2011-4109.
  • Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasisGalindo H, Suraokar M, Behrens C, Woods D, Kalhor N, Aldape K, Fujimoto J, Herbst R, Erickson H, Wistuba I. Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasis Cancer Research 2011, 71: 5166-5166. DOI: 10.1158/1538-7445.am2011-5166.
  • Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer modelsTakahashi O, Komaki R, Smith P, Jürgensmeier J, Ryan A, Bekele B, Wistuba I, Jacoby J, Korshunova M, Biernacka A, Erez B, Hosho K, Herbst R, O'Reilly M. Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models Cancer Research 2011, 71: 629-629. DOI: 10.1158/1538-7445.am2011-629.
  • Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancerIhle N, Herbst R, Kim E, Wistuba I, Lee J, Blumenschein G, Tsao A, Chen L, Zhang S, Alden C, Tang X, Liu S, Stewart D, Papadimitrakopoulou V, Heymach J, Tran H, Hicks M, Erasmus J, Gupta S, Minna J, Larsen J, Lippman S, Hong W, Powis G. Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer Cancer Research 2011, 71: 955-955. DOI: 10.1158/1538-7445.am2011-955.
  • Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)Heymach J, Saintigny P, Kim E, Byers L, Lee J, Coombes K, Diao L, Wang J, Tran H, Fan Y, Tsao A, Blumenschein G, Papadimitrakopoulou V, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna J, Herbst R, Lippman S, Hong W, Wistuba I. Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) Cancer Research 2011, 71: lb-88-lb-88. DOI: 10.1158/1538-7445.am2011-lb-88.
  • 366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinaseJimeno A, Herbst R, Falchook G, Messersmith W, Camidge D, Peterson S, Hausman D, Kurzrock R, Eckhardt S, Hong D. 366 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase European Journal Of Cancer Supplements 2010, 8: 116. DOI: 10.1016/s1359-6349(10)72073-5.
  • The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with RadiotherapyWei X, Allen P, Blumenschein G, Hong W, Herbst R, O'Reily M, Heymach J, Erasmus J, Lee J, Komaki R. The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s498. DOI: 10.1016/j.ijrobp.2010.07.1165.
  • Predictive Implications of KRAS and EGFR Gene Mutations in Non-small Cell Lung Cancer Treated with Radiation TherapyLikhacheva A, Thomas J, Kim E, Allen P, Komaki R, Cox J, Herbst R, Welsh J. Predictive Implications of KRAS and EGFR Gene Mutations in Non-small Cell Lung Cancer Treated with Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s128-s129. DOI: 10.1016/j.ijrobp.2010.07.323.
  • First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.Burris H, Rodon J, Sharma S, Herbst R, Tabernero J, Infante J, Silva A, Demanse D, Hackl W, Baselga J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2010, 28: 3005-3005. DOI: 10.1200/jco.2010.28.15_suppl.3005.
  • Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.Tibes R, Falchook G, Von Hoff D, Weiss G, Iyengar T, Kurzrock R, Pestano L, Lowe A, Herbst R. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. Journal Of Clinical Oncology 2010, 28: 3076-3076. DOI: 10.1200/jco.2010.28.15_suppl.3076.
  • Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.Jimeno A, Herbst R, Falchook G, Messersmith W, Hecker S, Peterson S, Hausman D, Kurzrock R, Eckhardt S, Hong D. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Journal Of Clinical Oncology 2010, 28: 3089-3089. DOI: 10.1200/jco.2010.28.15_suppl.3089.
  • Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.Johnson B, Ryan A, Heymach J, Stephens C, Kennedy S, Langmuir P, Herbst R. Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. Journal Of Clinical Oncology 2010, 28: 7516-7516. DOI: 10.1200/jco.2010.28.15_suppl.7516.
  • Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.Herbst R, Blumenschein G, Kim E, Lee J, Tsao A, Alden C, Liu S, Stewart D, Wistuba I, Hong W. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Journal Of Clinical Oncology 2010, 28: 7609-7609. DOI: 10.1200/jco.2010.28.15_suppl.7609.
  • Abstract 1397: VEGFR signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of chemotherapy and radiation in an orthotopic human lung cancer modelTakahashi O, Komaki R, Tailor R, Jürgensmeier J, Ryan A, Smith P, Jacoby J, Hosho K, Korshunova M, Erez B, Herbst R, O'Reilly M. Abstract 1397: VEGFR signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of chemotherapy and radiation in an orthotopic human lung cancer model Cancer Research 2010, 70: 1397-1397. DOI: 10.1158/1538-7445.am10-1397.
  • Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) programSaintigny P, Byers L, Zhang L, Yordy J, Tang X, Girard L, Lang W, Fan Y, Ji L, Lee J, Kim E, Hong W, Lippman S, Herbst R, Minna J, Wistuba I, Heymach J, Mao L. Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program Cancer Research 2010, 70: 1981-1981. DOI: 10.1158/1538-7445.am10-1981.
  • Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic targetIhle N, Kingston J, Gumbiner-Russo L, Byers L, Yordy J, Giri U, Heymach J, Minna J, Larsen J, Herbst R, Garth P. Abstract 306: KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic target Cancer Research 2010, 70: 306-306. DOI: 10.1158/1538-7445.am10-306.
  • Abstract 3435: VEGF or VEGF and EGF receptor signaling inhibition by cediranib or vandetanib enhances the therapeutic effects of chemoradiation in an orthotopic small cell lung cancer modelHosho K, Komaki R, Tailor R, Ryan A, Jürgensmeier J, Smith P, Jacoby J, Takahashi O, Korshunova M, Erez B, Herbst R, O'Reilly M. Abstract 3435: VEGF or VEGF and EGF receptor signaling inhibition by cediranib or vandetanib enhances the therapeutic effects of chemoradiation in an orthotopic small cell lung cancer model Cancer Research 2010, 70: 3435-3435. DOI: 10.1158/1538-7445.am10-3435.
  • Abstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma modelJacoby J, Erez B, Takahashi O, Korshunova M, Hosho K, Powis G, O'Reilly M, Herbst R. Abstract 3632: Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma model Cancer Research 2010, 70: 3632-3632. DOI: 10.1158/1538-7445.am10-3632.
  • Abstract 794: Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodologyYan W, Shih J, Raso M, Rodriguez-Canales J, Behrens C, Papadimitrakopoulou V, Herbst R, Emmert-Buck M, Wistuba I, Erickson H. Abstract 794: Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology Cancer Research 2010, 70: 794-794. DOI: 10.1158/1538-7445.am10-794.
  • BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination)Hong W, Herbst R, Kim E. BATTLE (Biomarker-based Approach of Targeted Therapy for Lung Cancer Elimination) 2010 DOI: 10.21236/ada542458.
  • IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities)Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative Treatments and Therapeutic Modalities) 2010 DOI: 10.21236/ada525846.
  • Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534)Hong D, Davis D, Naing A, Fu S, Falchook G, Ricks L, Bekele N, Mittleman D, Liu W, Ivy P, Herbst R, Kurzrock R. Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534) Molecular Cancer Therapeutics 2009, 8: a4-a4. DOI: 10.1158/1535-7163.targ-09-a4.
  • Abstract B139: Molecular pharmacology and antitumor activity of PHT-427 a novel AKT/PDPK1 pleckstrin homology domain inhibitorPowis G, Moses S, Zhang S, Du-Cuny L, Song Z, Herbst R, Jacoby J, Kirkpatrick L, Mash E, Meuillet E. Abstract B139: Molecular pharmacology and antitumor activity of PHT-427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor Molecular Cancer Therapeutics 2009, 8: b139-b139. DOI: 10.1158/1535-7163.targ-09-b139.
  • 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trialEberhardt W, Johnson B, Sun Y, Germonpré P, Saijo N, Zhou C, Wang J, Tada H, Kennedy S, Herbst R. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial European Journal Of Cancer Supplements 2009, 7: 505. DOI: 10.1016/s1359-6349(09)71714-8.
  • Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009Xu B, Lee D, Ranganathan A, Gandara D, Herbst R, Lara P. Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009 Clinical Lung Cancer 2009, 10: 217-222. DOI: 10.3816/clc.2009.n.029.
  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)Herbst R, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy S, Johnson B. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC) Journal Of Clinical Oncology 2009, 27: cra8003-cra8003. DOI: 10.1200/jco.2009.27.18_suppl.cra8003.
  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)Herbst R, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy S, Johnson B. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC) Journal Of Clinical Oncology 2009, 27: cra8003-cra8003. DOI: 10.1200/jco.2009.27.18s.cra8003.
  • SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC)Franklin W, Gandara D, Kim E, Herbst R, Moon J, Redman M, Olsen C, Hirsch F, Mack P, Kelly K. SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC) Journal Of Clinical Oncology 2009, 27: 11076-11076. DOI: 10.1200/jco.2009.27.15_suppl.11076.
  • Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitorJimeno A, Hong D, Hecker S, Clement R, Kurzrock R, Pestano L, Hiscox A, Leos R, Kirkpatrick D, Eckhardt S, Herbst R. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor Journal Of Clinical Oncology 2009, 27: 3542-3542. DOI: 10.1200/jco.2009.27.15_suppl.3542.
  • Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory studySaura C, Baselga J, Herbst R, del Campo J, Marotti M, Tessier J, Collins B, Heymach J. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study Journal Of Clinical Oncology 2009, 27: 6023-6023. DOI: 10.1200/jco.2009.27.15_suppl.6023.
  • Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC)Gold K, Lee J, Rice D, Tse W, Stewart D, Wistuba I, Herbst R, Lippman S, Hong W, Kim E. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC) Journal Of Clinical Oncology 2009, 27: 7566-7566. DOI: 10.1200/jco.2009.27.15_suppl.7566.
  • S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II studyGandara D, Kim E, Herbst R, Moon J, Redman M, Dakhil S, Hirsch F, Mack P, Franklin W, Kelly K. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study Journal Of Clinical Oncology 2009, 27: 8015-8015. DOI: 10.1200/jco.2009.27.15_suppl.8015.
  • KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536Mack P, Holland W, Redman M, Lara P, Snyder L, Hirsch F, Franklin W, Kim E, Herbst R, Gandara D. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536 Journal Of Clinical Oncology 2009, 27: 8022-8022. DOI: 10.1200/jco.2009.27.15_suppl.8022.
  • Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial programKim E, Herbst R, Lee J, Blumenschein G, Tsao A, Wistuba I, Alden C, Gupta S, Stewart D, Hong W. Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program Journal Of Clinical Oncology 2009, 27: 8024-8024. DOI: 10.1200/jco.2009.27.15_suppl.8024.
  • Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie S, Armand J, Shepherd F, Herbst R. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514 Journal Of Clinical Oncology 2009, 27: 8098-8098. DOI: 10.1200/jco.2009.27.15_suppl.8098.
  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)Herbst R, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy S, Johnson B. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC) Journal Of Clinical Oncology 2009, 27: cra8003-cra8003. DOI: 10.1200/jco.2009.27.15_suppl.cra8003.
  • Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trialZinner R, Herbst R, Fossella F, Johnson F, Karp D, Kies M, Heymach J, Price J, Lippman S, Erasmus J. Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trial Journal Of Clinical Oncology 2009, 27: e19069-e19069. DOI: 10.1200/jco.2009.27.15_suppl.e19069.
  • IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities)Hong W, Herbst R. IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities) 2009 DOI: 10.21236/ada504658.
  • In ReplyHirsch F, Herbst R, Olsen C, Chansky K, Crowley J, Kelly K, Franklin W, Bunn P, Varella-Garcia M, Gandara D. In Reply Journal Of Clinical Oncology 2009, 27: 465-467. DOI: 10.1200/jco.2008.20.0873.
    <